Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.

Wilson C, Lin JE, Li P, Snook AE, Gong J, Sato T, Liu C, Girondo MA, Rui H, Hyslop T, Waldman SA.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2328-37. doi: 10.1158/1055-9965.EPI-14-0440. Epub 2014 Oct 10.

2.

Accurate and precise DNA quantification in the presence of different amplification efficiencies using an improved Cy0 method.

Guescini M, Sisti D, Rocchi MB, Panebianco R, Tibollo P, Stocchi V.

PLoS One. 2013 Jul 8;8(7):e68481. doi: 10.1371/journal.pone.0068481. Print 2013.

3.

Molecular staging of node negative patients with colorectal cancer.

Hyslop T, Waldman SA.

J Cancer. 2013;4(3):193-9. doi: 10.7150/jca.5830. Epub 2013 Mar 1.

4.

Guanylyl cyclase C as a biomarker in colorectal cancer.

Hyslop T, Waldman SA.

Biomark Med. 2013 Feb;7(1):159-67. doi: 10.2217/bmm.12.90. Review.

5.

Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.

Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA.

Cancer. 2012 May 1;118(9):2532-40. doi: 10.1002/cncr.26516. Epub 2011 Sep 1.

6.

Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer.

Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA.

Clin Cancer Res. 2011 May 15;17(10):3293-303. doi: 10.1158/1078-0432.CCR-10-3113. Epub 2011 Feb 9.

7.

GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients.

Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA.

Expert Rev Mol Diagn. 2009 Nov;9(8):777-85. doi: 10.1586/erm.09.67.

8.

Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.

Waldman SA, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J, Bonaccorso C, Li Y, Weinberg DS.

JAMA. 2009 Feb 18;301(7):745-52. doi: 10.1001/jama.2009.141.

9.
10.

Supplemental Content

Support Center